Cas9 Stable Cell Line - KGN

The Cas9 Stable Cell Line - KGN is a cutting-edge tool in gene research, combining the unique biological characteristics of KGN cells with the precision of CRISPR-Cas9 technology. Derived from human ovarian granulosa cell tumors, the KGN cell line is renowned for its stable expression of the follicle-stimulating hormone (FSH) receptor and key reproductive hormones. These cells retain the characteristics of primary granulosa cells, making them a valuable resource for studying ovarian physiology and pathology. The Cas9 stable cell line – KGN – is genetically engineered to constitutively express the Cas9 nuclease, enabling highly efficient and targeted genome editing without transient transfection. This cell line exhibits robust growth, stable morphology, and hormone responsiveness in vitro – key characteristics that ensure experimental reproducibility.

The Cas9 Stable Cell Line - KGN holds broad promise for applications in reproductive biology and disease modeling. Researchers utilize it for high-throughput functional genomics screening to identify genes regulating follicle development, steroid production, and ovulation pathways. Its hormonal response characteristics allow researchers to study the mechanisms of polycystic ovary syndrome (PCOS) by knocking out candidate genes (such as FSHR or CYP19A1) and monitoring the hormonal cascade. In cancer research, this cell line can be used to construct granulosa cell tumor models by targeting mutant FOXL2 or TGF-β pathway genes, thereby enabling drug sensitivity testing against oncogenic variants. Drug developers use this cell line to construct precise knock-in models of hormone receptor polymorphisms to validate targets for infertility treatment. Furthermore, its CRISPR-ready platform accelerates research on epigenetic regulators of ovarian aging, providing new insights into fertility preservation.